Teriparatide
Also known as Forteo, PTH(1-34), PTH 1-34, Bonsity
Teriparatide (Forteo) is an approved daily injection — a piece of parathyroid hormone — that stimulates new bone growth to treat severe osteoporosis.
Recombinant N-terminal fragment of parathyroid hormone (PTH 1-34) used to build bone in severe osteoporosis. Dosed once daily subcutaneously.
Mechanism of action
Intermittent PTH-receptor activation favors osteoblastic bone formation over resorption, raising bone mineral density.
Approved drug (Forteo). Serum half-life is ~1 h after SC dosing even though the biologic effect lasts longer. The former osteosarcoma boxed warning (rodent data) was removed in 2020.
Track Teriparatide for free
Log your doses and PeptideBuddy models Teriparatide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free